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Abstract 
Background: For more than 30 years, drug consumption rooms (DCRs) have been implemented in Western coun-
tries. DCRs are supported by a large body of evidence about public safety and public health effectiveness. However, 
a political consensus has never been achieved in Belgium on amending the existing law that explicitly penalises the 
supply of a room for facilitating drug use. Despite this adverse legal and policy framework, a DCR opened in the city 
of Liège in 2018. In this case report, we applied the theoretical framework proposed by Shiffman and Smith for policy 
agenda setting, in order to describe and assess how political and legal barriers were overcome in the process of open-
ing the DCR.
Case presentation: For some years, fieldworkers and some city policymakers argued for DCR implementation in Bel-
gium, but without gaining the support of the national authorities, mainly for ideological reasons. In order to address 
this debate, a feasibility study of DCR implementation in Belgian cities was commissioned. At the national level, an 
institutional debate took place about the political responsibility for DCRs as a public health intervention, as health 
care is mainly a matter of regional policy. The lack of consensus led to a situation of political deadlock. Meanwhile, the 
publication of the study report and the context of local elections offered an opportunity for Liège authorities to reig-
nite the local debate on DCRs. At the local level, law enforcement, care professionals, residents, users, and the press 
were all involved in the implementation process. Therefore, a local consensus was formed and despite the absence 
of any national legal change, the DCR opened 1 month before the local elections. It has been working without major 
medical or legal incident since then. Incidentally, the mayor of Liège was re-elected.
Conclusions: Although the lack of a legal framework may engender instability and affect longer-term effectiveness, 
the DCR implementation in Liège was successful and was based on a local consensus and effective communication 
rather than on an appropriate legal framework. The experience provides lessons for other cities that are considering 
opening a DCR despite an adverse legal and political context.
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Background
Drug consumption rooms (DCRs) are legally sanctioned 
public health facilities that offer a hygienic environment 
where people can use pre-obtained drugs in a non-judge-
mental environment and under the supervision of trained 
staff [1–3]. They constitute a highly specialised service 
within a range of services for people who use drugs 
(PWUD). DCRs are embedded in comprehensive local 
strategies in order to reach different individuals and ful-
fil the community needs that arise from illicit drug use 
[4–7]. DCRs have been operating in Europe, Canada, 
and Australia for the last three decades. Since the first 
officially sanctioned facility opened in Berne in 1986, the 
number of DCRs has risen and has reached more than 90 
today [3, 8, 9].
Although DCRs vary in operational procedures and 
design, their aims are oriented towards public health 
and safety objectives. In terms of public health, the over-
all rationale behind DCRs is one of reaching out to, and 
addressing the problems of, specific high-risk populations 
of PWUD, especially people who inject drugs and those 
who consume in public [3]. For this group, DCRs aim 
to reduce the risk of transmission of blood-borne infec-
tions, to reduce the likelihood of morbidity and mortality 
resulting from overdose, and to help PWUD avoid other 
harms associated with drug consumption under unhy-
gienic or unsafe conditions [4, 5, 7, 10]. DCRs also aim 
to reach and maintain contact with socially marginalised 
groups and to facilitate access to health and social ser-
vices, including addiction treatment programmes [11–
16]. In terms of public safety, DCRs aim to contribute to a 
reduction in drug use in public places and in the presence 
of discarded needles and other related public order prob-
lems linked with open drug scenes [7, 17].
A substantial body of evidence has accumulated over 
the past three decades to support the effectiveness of 
DCRs in achieving their primary health and public order 
objectives, and therefore supports their role within a con-
tinuum of services for PWUD [6, 7, 18]. With regards 
to legislation, the European Union described DCRs as 
an effective measure for risk and harm reduction in its 
2017–2020 Drug Action Plan [19], as did the Interna-
tional Narcotics Control Board (INCB) in 2016 [20]. An 
abundance of studies has also demonstrated that feared 
negative consequences of opening a DCR are not borne 
out by experience: DCRs do not increase drug use in 
their vicinity, nor do they encourage young people to ini-
tiate drug use [21, 22]. Despite the scientific evidence and 
international legislation supporting DCRs, there continue 
to be social and structural barriers to the implementation 
of this public health intervention in communities across 
the globe [23, 24]. Accordingly, the debate about imple-
menting new DCRs remains high on the political agenda 
in a number of countries worldwide, including the United 
Kingdom and the United States [25–30].
From a legal point of view, international conventions 
allow flexibility in the establishment of DCRs when 
national legislation specifically acknowledges that these 
facilities are part of a public heath, harm-reduction strat-
egy [31]. In several countries, this international frame-
work has been sufficient to permit the implementation of 
DCRs [32], as was the case in Switzerland in 1986 [33] 
and in Germany in the mid-1990s [30, 34]. However, 
other countries were of the opinion that the establish-
ment of DCRs required change in their legislation. That 
was the case, for example, in France and Luxembourg. In 
particular, the French legislation was modified in order 
to allow DCRs in the framework of a medical experi-
ment [35], while new legislation in Luxembourg explicitly 
excluded DCRs from the articles that punished drug pos-
session and drug-use facilitation [31]. Such exceptions 
were also introduced in the Canadian legislation [36].
In Belgium, the implementation of DCRs conflicts with 
the Belgian federal Drug Law of 1921, which makes it a 
punishable offence to make a room available to facili-
tate the use of illegal drugs. Since the beginning of the 
2000s, several associations of field professionals, local 
policymakers, and scientific organisations have pleaded 
for a modification of the law and supported the imple-
mentation of DCRs in Belgian cities [37–40]. However, a 
political consensus has never been achieved on amend-
ing the law and allowing implementation. In addition, 
the Belgian policy system is highly fragmented and 
complex. While the penal and criminal law is under the 
responsibility of the federal, i.e. national authority, most 
prevention and health policy responsibilities have been 
devolved to the federated authorities (regions and com-
munities), each of which has its own government and 
majority. It is unclear whether the establishment of DCRs 
comes under the authority of the federal or federated 
governments. Against all odds, however, a DCR opened 
in the city of Liège in September 2018, 1  month before 
local elections. Against that background, this study aims 
to assess the drivers that put DCR implementation on the 
political agenda until its effective implementation, and to 
look at how the adverse legal and political context was 
overcome.
We applied the policy agenda framework proposed by 
Shiffman and Smith [41] in order to organise the pres-
entation of the key elements that favoured the imple-
mentation of a DCR in Liège. That framework was 
initially developed to analyse why some health initiatives 
receive priority from political leaders and others do not, 
i.e. the so-called policy agenda setting [42–44]. Shiff-
man and Smith developed the framework for examin-
ing health policy initiatives on maternal mortality in 
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developing countries. Since then, it has been applied to 
many other health policy fields, including chronic and 
non-communicable diseases, mental health, and drug 
policies [45–48]. The framework proposes four catego-
ries of key factors: [1] the intrinsic characteristics of the 
issue, [2] the political context, [3] the power of the actors 
involved in the policy initiative, and [4] the power of the 
ideas used to describe the issue (i.e. policy formulation). 
According to Shiffman and Smith, initiatives are more 
likely to attract political support when they share spe-
cific features in all categories [41]. Firstly, regarding issue 
characteristics, a health policy initiative is more likely to 
attract political support when the issue is considered to 
be sufficiently severe to deserve attention. That severity, 
however, has to be balanced against other possible pri-
orities that are deemed to be less severe. The importance 
of an issue is reinforced if credible indicators exist that 
show clearly both the issue’s severity and interventions 
that are deemed to be feasible and effective in tackling it. 
Secondly, the impact of the political context on agenda 
setting is mainly driven by policy windows, i.e. exter-
nal conditions that are perceived as favourable for tack-
ling the issue. A textbook example of a favourable policy 
window is the holding of elections, as they create a con-
text for proposing and discussing new policy initiatives. 
Thirdly, the policy agenda setting is determined by the 
power of actors, i.e. the policy cohesion that derives from 
the existence of strong leadership, guiding institutions 
that could operate the initiative, and civil society mobili-
sation. Finally, “the power of ideas” considers the different 
ways in which actors involved with the issue understand 
and portray it [49]. Therefore, the power of ideas is based 
on the capacity of actors to formulate the issue and 
potential measures to tackle it in a way that makes it pos-
sible to achieve a consensus, both internal and external. 
Internal consensus refers to the level of agreement across 
stakeholders and the policy community on the definition 
and terms of the issue. External consensus is the extent 
to which a consensus is also achieved outside the stake-
holder and policy community, e.g. in public opinion and 
the media. In this study, we have examined these char-
acteristics in the context of the moves to open a DCR in 
Liège.
This case report results from our involvement in the 
national feasibility study on DCR implementation in Bel-
gium that was carried out a few months before the open-
ing of the DCR in Liège. During that study, we carried out 
a series of qualitative interviews with relevant stakehold-
ers (i.e. prosecutorial authorities, law enforcement, local 
policymakers, and health and social care professionals) 
as well as PWUD, in the five major cities of the country, 
including Liège. In addition, we followed up the events 
that occurred after the publication of the study report 
and we collected press releases regarding the topic of the 
potential DCR and subsequently the actual opening of a 
DCR. Finally, we had additional contacts with the Liège 
authorities and DCR providers, in order to appraise the 
context of the opening of the DCR.
Case presentation
Local characteristics of the issue
Until the 1960s, Liège, one of the largest industrial cit-
ies in Belgium, had thriving mining and steel industries 
[50, 51]. As happened in many other coal-based indus-
trial areas, its industry declined from the end of the 
1970s and the city experienced a socio-economic cri-
sis, with increased poverty and unemployment in some 
neighbourhoods [52]. The socio-economic decline was 
accompanied by an increase in illicit drug consumption 
and trafficking [53]. In addition, it is usually considered 
that the geographical position of the city, near the Dutch 
city of Maastricht and the German city of Aachen, is stra-
tegic in terms of the illicit drug market [54]. In 2016, in 
the Walloon region (3.5 million inhabitants) in south-
ern Belgium, the number of heroin users was estimated 
at 12,000, including 2500 people who inject drugs [55]. 
Although it is difficult to estimate the size of this hid-
den and marginalised population, several sources suggest 
that the size of the DCR target group in the inner city 
of Liège (200,000 inhabitants) is about 300 PWUD [56]. 
The geographic landscape of the local drug scene is not 
spread across the city but is concentrated in the down-
town area near the train station, bus station, and shop-
ping malls [31]. In 2013, between 352 and 470 people 
who inject drugs attended the syringe exchange counters 
[56]. In 2017, 134,500 syringes were distributed to 550 
unique PWUD [56]. The Institute of Forensic Medicine 
of Liège recorded 35 cases of fatal intoxication by drug 
use between 2011 and 2013 [56]. The local police drew 
up 1745 reports related to narcotics in 2016, and 2197 in 
2017 [56]. All these figures indicate that the public health 
and public safety issues related to drug use are becoming 
more severe.
Over recent years, the City of Liège has developed 
innovative interventions to tackle issues related to drug 
use. In 2011, the city supported a 2-year pilot interven-
tion based on heroin-assisted treatment delivery in the 
form of a clinical randomised controlled trial, called the 
treatment assisted by diacetylmorphine (TADAM) pro-
ject [39]. With the approval of the prosecutorial authori-
ties and the “Federal Agency for Medicines and Health 
Products” (National Belgian medicine agency), in the 
context of a scientific medical experiment in line with 
UN drug conventions, a derogation from the federal Drug 
Law was granted, allowing the medical prescription of 
diacetylmorphine (heroin) and the availability of a room 
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for its supervised consumption [57]. The pilot project 
was completed in 2013 and its evaluation showed posi-
tive outcomes for PWUD [39, 58]. The only caveat was 
the cost–benefit analysis, which showed that, compared 
to methadone maintenance treatment, diacetylmorphine 
treatment resulted in an annual extra cost per patient of 
almost €20,000, which was not offset by societal benefits 
[59]. The limitations of this analysis were, however, that 
it only involved a small sample of 74 PWUD randomised 
between the two groups, and its short follow-up period 
of 12 months. Authorities used this negative cost–benefit 
analysis and the absence of an amendment to the federal 
Drug Law to close down the pilot project and the facility 
[57, 59].
In the light of that experiment, the mayor of Liège 
undertook several initiatives to support the establish-
ment of a DCR in the city. In particular, in 2014, he 
introduced a bill in the federal parliament to amend the 
federal Drug Law in order to permit the establishment 
of a DCR [60]. However, the bill never reached the level 
of consensus required. By the end of 2016, the drug pol-
icy department of the Belgian Ministry of Public Health 
published a working paper on DCRs in Belgium [61]. 
One of the seven conclusions of that paper was that “if 
one wishes to implement a DCR, a prior feasibility study 
is essential. In addition to the above-mentioned elements, 
the budget and legal aspects, including the issues regard-
ing liability of the health care providers and the authori-
ties in case of overdose, must be thoroughly examined” 
[61]. In 2017, the feasibility study was carried out in the 
five largest Belgian cities, including Liège [31]. The aims 
of this study were [1] to provide an up-to-date overview 
of the effectiveness of, models of, and barriers to DCRs 
worldwide, [2] to conduct an analysis of the legal frame-
work for the implementation of a DCR in Belgium, [3] to 
conduct a qualitative feasibility study with stakeholders 
(i.e. policymakers, policy administration, law enforce-
ment, criminal justice, drug treatment services, outreach 
services, and harm reduction services and social welfare 
services) and PWUD from each of the five Belgian cities, 
and [4] to formulate recommendations for the implemen-
tation of DCRs should they be deemed necessary. The full 
report of the feasibility study has been published else-
where [31]. The Liège local authorities used this feasibil-
ity study in the development of their policy.
Political context
The feasibility study showed that most stakeholders 
in Liège (prosecutorial authorities, law and enforce-
ment professionals, local policymakers, and health and 
social care professionals), as well as PWUD, agreed that 
implementing a DCR would be useful [31]. The ear-
lier TADAM experiment was perceived as positive in 
terms of implementation in the neighbourhood, impact 
on public safety issues, and PWUD health and wellbe-
ing by most stakeholders. The TADAM experiment also 
indicated the commitment of local authorities in rela-
tion to drug use issues in the city since the early 2000s 
(i.e. local policymakers and law enforcement). Indeed, 
when considering several technical options for the estab-
lishment of a DCR in their city, e.g. regarding opening 
hours, inclusion/exclusion criteria, and the type of per-
sonnel needed, all stakeholders interviewed in the feasi-
bility study referred positively to the previous TADAM 
experience [31]. The publication of the national feasibility 
study in February 2018 [31] was used by the mayor of the 
city of Liège as an opportune political window to reignite 
the political debate on DCRs in the context of local elec-
tions. In the same period, press articles were published 
about the drug scene in the city of Liège (on the numbers 
of drug users and the prevalence of drug-related harm, 
consumption in public spaces, discarded syringes, and 
drug-related crime), as were articles commenting on the 
results of the feasibility study [54, 62]. Against that back-
ground, the mayor organised several meetings in the city 
to discuss both his political programme for the local elec-
tions and the results of the feasibility study [63, 64]. Sev-
eral meetings were organised with the local prosecutorial 
authorities and the police in order to anticipate legal and 
security issues. Meetings also took place with residents, 
in order to discuss the potential effects of a DCR on the 
health and welfare of PWUD, as well as on public safety 
and nuisances related to drug use in the city centre, bear-
ing in mind the earlier positive TADAM experience. 
These meetings were organised with the participation of 
different local policymakers, including from the opposi-
tion and, despite the electoral context, which might have 
favoured confrontation, a broad political consensus was 
reached across all the parties represented on the city 
council in support of the DCR [64].
The power of actors
Fragmentation of policy responsibilities is one of the key 
features of the Belgian policy system [65, 66]. In par-
ticular, health policy responsibilities are shared within a 
complex system of different policy authorities: the fed-
eral (national) authority and several levels of federated 
authorities (regions and communities, whose territories 
overlap in some cases). A single health policy decision 
usually requires the agreement of at least two differ-
ent authorities. By contrast, public safety is mainly the 
responsibility of the federal authorities, although local 
authorities have extensive autonomy for local initiatives. 
As a result, decision-making usually involves lengthy 
negotiation processes between diverse stakeholder 
groups and authorities, and decisions are driven by a high 
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level of corporatism, with each segment aiming to pro-
tect its particular interests [66]. In addition, the Belgian 
policy system is characterised by a lack of cohesion, by 
multiple, sometimes competing, guiding institutions, and 
by weak overall leadership [67]. At the same time, this 
kind of system also leaves extensive room and autonomy 
for local initiatives and local leadership.
During the 2014–2019 legislature, no consensus was 
reached on new drug policy initiatives at the federal level 
[68]. This meant that there was no support for DCRs 
or for an amendment to the Drug Law from the federal 
government during the legislature. The Belgian federal 
government is usually formed by coalitions made up of 
different parties. Although some of the parties were not 
opposed to DCRs and were keen to consider the scien-
tific evidence on their effectiveness, some other parties 
made their reluctance clear. Traditionally, when there 
is no consensus among members of the government on 
social issues, no decision is made [66], leading to a politi-
cal deadlock. The situation, however, left room for local 
authority initiatives. Several local policy stakeholders 
pleaded for change, in particular regarding the possibil-
ity of implementing DCRs and other harm-reduction 
initiatives, particularly in the French-speaking commu-
nity [69–71]. In the city of Liège, the local authorities 
had, since 2003, been developing a local drug policy plan 
that emphasised the need for a DCR in the city [72, 73]. 
In addition, the mayor had publicly taken the lead on a 
policy that favoured the opening of a DCR.
The power of ideas
The key policy formulation regarding DCRs is related to 
their ambiguous position between the penal and public 
health domains. Within the federal structure of the Bel-
gian state, the Belgian Drug Law (1921), which is a penal 
law, is under the responsibility of the federal, i.e. national 
authorities, while the main responsibility for health pol-
icy, including prevention and harm reduction, is regional. 
After taking note of the lack of political willingness to 
amend the penal law at the federal level, the mayor of 
Liège obtained the support of the Walloon regional 
authority in the form of a resolution acknowledging that 
DCRs are an effective tool for harm reduction [74, 75]. 
As a result, an institutional debate took place about the 
potential conflict of policy responsibilities between the 
regions and the federal authorities. Some policymakers in 
the Brussels region also proposed regional regulation of 
harm-reduction interventions, including DCRs, arguing 
that health was a regional competence [76]. A formula-
tion of policy on the issue that clearly presented DCRs 
as an instrument for public health led to an internal con-
sensus among French-speaking stakeholders (in Brussels 
and Wallonia). This policy formulation helped to block 
possible counter-initiatives against the implementation of 
the DCR, e.g. from the federal authorities. Interestingly, 
however, the external consensus, i.e. involving the local 
stakeholders and residents, was achieved by emphasising 
the benefits of a DCR in terms of tackling public safety 
nuisances. Local authorities were successful in presenting 
the policy issue and intervention using both the public 
health and public safety frameworks.
The establishment of the DCR
Taking into account all the elements analysed within the 
four categories of Shiffman and Smith’s framework, the 
outcome was the opening of a DCR in Liège in Septem-
ber 2018, 1 month before the local elections, despite the 
adverse legal and federal policy framework. The DCR is 
funded by the city authorities and the Walloon region 
and is coordinated by the TADAM foundation that had 
managed the previous diacetylmorphine-assisted treat-
ment project. The DCR was established in the same 
premises, which already had the appropriate infrastruc-
ture, including eight injection booths and one room for 
drug smoking for twelve PWUD. These premises are 
located in the downtown area, close to the local drug 
scene. Before the opening of the DCR, a consultation 
with local stakeholders was organised in order to vali-
date the different operating criteria for the DCR (PWUD 
admission criteria, intake procedure, registration proce-
dure, opening hours, house rules and regulations, and 
staff required), based on the previous TADAM experi-
ence and the results of the feasibility study [31, 56]. The 
public prosecutor’s office published a note explaining 
that it would not initiate prosecution against the DCR, its 
staff, or its users, although it would decide, depending on 
the circumstances, whether to prosecute the institution 
in the event of a complaint from a third party (public or 
civil party) [77]. During the week before the opening, the 
residents of the area were invited to visit the room and 
the press reported positively on the event [63]. Inciden-
tally, the mayor was re-elected in October 2018.
As previously explained, the DCR’s target public was 
estimated at 300 PWUD [56]. Preliminary data gath-
ered by the DCR providers stated that after 3  months, 
the DCR had reached 72% (216 PWUD) of its estimated 
target public, and 121% (363 PWUD) after 6  months, 
without any major medical or legal incident. Over the 
first 6 months, the average number of daily visitors was 
35 (range 4–78). Of all registered visits (N = 6292), drugs 
were injected on 42% of visits and inhaled on 55%. The 
main drugs consumed were heroin (74% of visits) and 
cocaine (20% of visits). In addition, 44 PWUD have 
changed their route of administration from injection to 
inhalation. Two overdose events were adequately man-
aged; these required resuscitation by the DCR staff and 
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evacuation to an emergency department, without severe 
consequences.
Discussion and conclusions
Despite the lack of political consensus at the national 
level and the lack of a legal framework, a lack that might 
lead to instability and affect longer-term effectiveness, 
the DCR implementation in Liège has been successful. 
The four categories of Shiffman and Smith’s framework 
help to clarify how the local characteristics of the issue, 
the policy context, the power of actors, and formulation 
of policy on the issue contributed to this outcome. In the 
specific context of a long history of initiatives in relation 
to harm reduction in Liège, the implementation of the 
DCR was made possible, in the context of the local elec-
tions, by a consensus among local stakeholders (policy-
makers from the different parties, the public prosecutor’s 
office, law and enforcement professionals, health and 
social care professionals, and residents) and by a commu-
nication strategy that involved all these stakeholders and 
researchers. The local initiatives were feasible thanks to 
the commitment of the local authorities and the context 
of fragmentation and political deadlock at the national 
level.
The literature makes it clear that the lack of political 
consensus in national governments favouring the imple-
mentation of DCRs is mainly related to issues of morality, 
ideology, public acceptance, and negative media response 
and the associated political consequences [30, 78–81]. 
The strategy in Liège, however, proved to be successful in 
overcoming barriers of that kind. What is more, the local 
political support for DCR implementation was, in this 
case, a factor of popularity in the context of the elections.
One key element for the opening of the DCR has prob-
ably been the local consensus of stakeholders (prosecu-
torial authorities, law enforcement professionals, local 
policymakers, health and social care professionals, and 
residents). This consensus was made possible by the vis-
ible increase in public safety issues related to drug use 
over the last decade in the city and by the past experi-
ence of harm-reduction interventions, i.e. the TADAM 
pilot project. Local stakeholders and the population all 
agreed that the TADAM experience had been benefi-
cial and criticised its closure [31]. A second key element 
was the communication strategy and the consultation of 
local stakeholders, leading to their involvement through-
out the process of implementing the DCR. The publica-
tion of the feasibility study, which recalled the evidence 
on DCRs, and the context of the local elections helped to 
create momentum. The Vancouver experience also made 
it clear that one element of success in the implementation 
of their DCR was the consultation and involvement of 
key stakeholders, including the residents, in the process 
of establishing the DCR [82]. Indeed, consulting local 
stakeholders makes it possible to establish collaboration 
and a dialogue on the resolution of issues and misunder-
standings in relation to DCRs [82]. The emphasis on pub-
lic nuisances (consumption in public spaces, discarded 
syringes, and drug-related crime) in the formulation of 
the policy issue may have contributed to the involvement 
of local stakeholders and residents. In the Netherlands, 
the majority of DCR managers explained that the primary 
rationale for founding a DCR was the reduction of pub-
lic nuisances [83, 84]. In contrast, a policy formulation 
clearly presenting DCRs as a public health instrument 
has led to an internal consensus between policymakers at 
the level of the federated authorities.
Finally, the lack of political consensus at the national 
level left room for local leadership and autonomy for ini-
tiatives, in particular where there was a prior history of 
similar interventions. This kind of context has also been 
observed to an extent in France, for example. The case 
made by the Paris City Council for the opening of a DCR 
in 2010 and 2013 led to a compromise at the national 
level, with the French parliament adopting a new law 
that permitted DCRs as an experiment in 2016 [35, 85]. 
In Vancouver in 2003, the exemption granted by the then 
Canadian government, which allowed the opening of the 
DCR, followed the election of a new mayor in 2002, Larry 
Campbell, who had made the opening of a DCR in Van-
couver a key part of his programme [36, 86]. However, 
this bottom-up development of initiatives requires local 
powers and autonomy, which do not exist in all coun-
tries. For example, one study observed that the absence 
of DCRs in the UK, even though some cities wanted to 
open them, may reflect the limited power and autonomy 
of local authorities as compared to other countries, such 
as Germany [30].
However, the Liège initiative remains unstable and the 
lack of an appropriate legal framework may weigh on its 
long-term effectiveness. It remains unclear whether the 
courts would interpret the article of the federal Drug 
Law that punishes the facilitation of a room for drug use 
in a way that would rule out DCRs. The outcome of any 
such case remains unknown. The development of Belgian 
drug policy is characterised by a bottom-up approach, in 
which innovative interventions have often been initiated 
at a local level [87] and have only later become part of a 
legal framework. This has been particularly the case for 
harm-reduction interventions such as opioid substitute 
treatments [88], syringe exchange [89], and the organisa-
tion of drug-addiction treatments in prisons [90]. These 
harm-reduction interventions had no legal framework 
or were even illegal when they were implemented, but 
they were legalised or regularised over time. This might 
also happen to DCRs in Belgium. Since the DCR was 
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established in Liège, other Belgian cities, particularly in 
the French-speaking community, have developed plans 
for establishing their own DCRs in the near future, 
including Brussels, Charleroi, and Namur [91–93]. In 
Charleroi, the city council came out in favour of the 
implementation of a DCR [93]. Finally, Brussels, which 
has its own regional government, approved a draft decree 
providing for the implementation of a DCR in the city 
during the next legislature as part of a broader, integrated 
regional drug policy [91, 94].
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